Galvus and Galvus Met in treatment of elderly patients with type 2 diabetes mellitu


如何引用文章

全文:

详细

In old age, the prevalence of type 2 diabetes mellitus (DM2) increases progressively, reaching 20 % among people older than 70 years. Elderly DM2 patients are a heterogeneous group with multiple comorbidities, high risk of hypoglycemia and susceptibility to side effects of drug therapy, which greatly complicates the treatment of this complex patient population. The risk of development of severe hypoglycemia, probably, is the most difficult problem in the treatment of elderly patients with diabetes mellitus. Incretins, including glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are the hormones released in the intestinal mucosa in response to a meal; they provide glucose-dependent stimulation of insulin secretion and suppression of postprandial glucagon secretion. Therapy based on incretins, including GLP-1 analogs and dipeptidyl peptidase-4 (DPP-4) inhibitors, can be considered as reasonable choice for older patients. These drugs are characterized by good tolerance, high efficacy and low risk of hypoglycemia. Recently, several meta-analyses on evaluation of the effectiveness and risks of treatment of elderly patients by DPP-4 inhibitor vildagliptin in monotherapy and in combination were published. The article analyses the published data on the use of Galvus (vildagliptin) and Galvus Met (vildagliptin + metformin) in a population of elderly patients.

参考

  1. Sloan FA, Bethel MA, Ruiz D Jr, Shea AM, Feinglos MN. The growing burden of diabetes mellitus in the US elderly population. Arch Intern Med 2008;168(2):192-99.
  2. Fagot-Campagna A, Bourdel-Marchasson I, Simon D. Burden of diabetes in an aging population: prevalence, incidence, mortality, characteristics and quality of care. Diabetes Metab 2005;31(2):5S35-5S52.
  3. Bourdel-Marchasson I, Berrut G. Caring the elderly diabetic patient with respect to concepts of successful aging and frailty. Diabetes Metab 2005;31(2):5S13-5S19.
  4. Abbatecola AM, Paolisso G, Corsonello A, Bustacchini S, Lattanzio F. Antidiabetic oral treatment in older people: does frailty matter? Drugs Aging 2009;26(suppl. 1):53-62.
  5. Bourdel Marchasson I, Doucet J, Bauduceau B, et al; ALFEDIAM/SFGG French-Speaking Group for Study of Diabetes in the Elderly. Key priorities in managing glucose control in older people with diabetes. J Nutr Health Aging 2009;13(8):685-91.
  6. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008;25(3):245-54.
  7. Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging 2004;21(8):511-30.
  8. Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging 2008;25(11):913-25.
  9. Mathieu C, Bollaerts K. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract Suppl 2007;154:29-37.
  10. Skyler JS, Bergenstal R, Bonow RO, et al; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009;119(2):351-57.
  11. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909.
  12. Kalyani RR, Saudek CD, Brancati FL, Selvin E. Association of diabetes, comorbidities, and A1c with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999-2006. Diabetes Care 2010;33(5):1055-60.
  13. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368(9548):1696-705.
  14. Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2010;70(16):2089-112.
  15. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naпve elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007;30(12):3017-22.
  16. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009;11(8):804-12.
  17. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50(6):1148-55.
  18. Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 2008;40(6):427-30.
  19. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11(2):157-166.
  20. Munshi M, Grande L, Hayes M, et al. Cognitive dysfunction is associated with poor diabetes control in older adults. Diabetes Care 2006;29(8):1794-99.
  21. Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10(11):1114-24.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##